Caixa Innvierte BioMed II

AELIX Therapeutics and Gilead Sciences Enter into a Clinical Research Collaboration Agreement to Evaluate a Therapeutic Vaccine and TLR7 Agonist Regimen for HIV Cure

AELIX Therapeutics S.L. (“AELIX”), a clinical-stage biotechnology company specialized in the discovery and development of immunotherapies for HIV infection, today announces that it has entered into a clinical research collaboration with Gilead Sciences, Inc. (“Gilead”), a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need, to jointly evaluate proprietary investigational products in a strategic clinical study aimed at achieving a functional cure of HIV infection.

| Read more |

Minoryx Therapeutics raises €21.3M in Series B funding round

Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces the completion of a Series B funding round of €21.3M. The proceeds will enable the company to expand the list of indications for its lead compound, MIN-102, as well as to conduct a new clinical trial for a second orphan central nervous system (CNS) indication.

| Read more |

ABAC Therapeutics Announces €16 Million Series A to Develop Therapeutic Solutions to Fight Antibiotic-Resistant Bacteria

ABAC Therapeutics (ABAC), a leader in pathogen-specific antibiotics, announced today the closing of a €16 million Series A round. The financing was led by Pontifax with participation from the Global Health Science Fund (jointly established by Quark Venture Inc. and GF Securities), Caixa Capital Risc, Debiopharm Innovation Fund and the existing investor Ferrer.

| Read more |

QIAGEN enters into agreement to acquire STAT-Dx, a Caixa Capital Risc portfolio company

STAT-Dx, a privately-held company developing the next generation of multiplex diagnostics for one-step, fully integrated molecular analysis of common syndromes. The system was unveiled in April 2017 at the European Congress of Clinical Microbiology (ECCMID) and received a first CE-IVD marking in January 2018.

| Read more |

MedLumics, a company owned by “la Caixa” and Ysios Capital, closes a financing round of 34.4 million euros

• Medlumics has closed a round of financing round of 34,4 million euros to bring their main product into the market, AblaView, an atrial fibrillation treatment in the field of cardiac arrhythmias.
• Medlumics is a company dedicated to medical technology for the treatment of cardiac diseases, with products based on photonic energy.
• Caixa Capital Risc and Ysios Capital invested in Medlumics in 2012 to support the company in its development.
• This has been the largest round in the history of the medical technology industry in Spain, and one of the largest in Europe.

| Read more |